Please assess the completion status of the following clinical trial:

Trial Title: Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed diagnosis of T2DM by standard criteria~2. Patients who have received a stable dose of SU for at least 12 weeks prior to Visit 1~3. HbA1c ≥7.5% to ≤ 11.0% at Visit 1 and Visit 3 (Week -1)~4. Age: ≥18 to ≤ 80 years at Visit 1.~5. BMI ≥ 20 and ≤ 40 kg/m\^2 at visit 1.~Exclusion Criteria:~1. FPG ≥ 270mg/dl (15.0 mmol/L) at Visit 1 or Visit 3 (Week -1)~2. Severe or repetitive hypoglycemia, as defined in section 3.1, during the run-in period (between Visit 2 and Visit 4)~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- vildagliptin (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).